Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell ; 74(3): 542-554.e5, 2019 05 02.
Article in English | MEDLINE | ID: mdl-30905509

ABSTRACT

Developing and adult tissues use different cis-regulatory elements. Although DNA at some decommissioned embryonic enhancers is hypomethylated in adult cells, it is unknown whether this putative epigenetic memory is complete and recoverable. We find that, in adult mouse cells, hypomethylated CpG dinucleotides preserve a nearly complete archive of tissue-specific developmental enhancers. Sites that carry the active histone mark H3K4me1, and are therefore considered "primed," are mainly cis elements that act late in organogenesis. In contrast, sites decommissioned early in development retain hypomethylated DNA as a singular property. In adult intestinal and blood cells, sustained absence of polycomb repressive complex 2 indirectly reactivates most-and only-hypomethylated developmental enhancers. Embryonic and fetal transcriptional programs re-emerge as a result, in reverse chronology to cis element inactivation during development. Thus, hypomethylated DNA in adult cells preserves a "fossil record" of tissue-specific developmental enhancers, stably marking decommissioned sites and enabling recovery of this epigenetic memory.


Subject(s)
DNA Methylation/genetics , Enhancer Elements, Genetic/genetics , Epigenomics , Histones/genetics , Animals , Gene Expression Regulation, Developmental/genetics , Mice
2.
J Biol Chem ; 293(52): 20137-20156, 2018 12 28.
Article in English | MEDLINE | ID: mdl-30389787

ABSTRACT

Myocilin (MYOC) was discovered more than 20 years ago and is the gene whose mutations are most commonly observed in individuals with glaucoma. Despite extensive research efforts, the function of WT MYOC has remained elusive, and how mutant MYOC is linked to glaucoma is unclear. Mutant MYOC is believed to be misfolded within the endoplasmic reticulum, and under normal physiological conditions misfolded MYOC should be retro-translocated to the cytoplasm for degradation. To better understand mutant MYOC pathology, we CRISPR-engineered a rat to have a MYOC Y435H substitution that is the equivalent of the pathological human MYOC Y437H mutation. Using this engineered animal model, we discovered that the chaperone αB-crystallin (CRYAB) is a MYOC-binding partner and that co-expression of these two proteins increases protein aggregates. Our results suggest that the misfolded mutant MYOC aggregates with cytoplasmic CRYAB and thereby compromises protein clearance mechanisms in trabecular meshwork cells, and this process represents the primary mode of mutant MYOC pathology. We propose a model by which mutant MYOC causes glaucoma, and we propose that therapeutic treatment of patients having a MYOC mutation may focus on disrupting the MYOC-CRYAB complexes.


Subject(s)
Cytoskeletal Proteins/metabolism , Eye Proteins/metabolism , Glaucoma/metabolism , Glycoproteins/metabolism , Mutation, Missense , Trabecular Meshwork/metabolism , alpha-Crystallin B Chain/metabolism , Amino Acid Substitution , Animals , Crystallins/genetics , Crystallins/metabolism , Cytoskeletal Proteins/genetics , Disease Models, Animal , Eye Proteins/genetics , Female , Glaucoma/genetics , Glaucoma/pathology , Glycoproteins/genetics , Humans , Male , Mice, Mutant Strains , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/metabolism , Protein Binding , Rats, Sprague-Dawley , Trabecular Meshwork/pathology , alpha-Crystallin B Chain/genetics
3.
Protein Expr Purif ; 147: 38-48, 2018 07.
Article in English | MEDLINE | ID: mdl-29475084

ABSTRACT

Myocilin (MYOC) is a secreted protein found in human aqueous humor (AH) and mutations in the MYOC gene are the most common mutation observed in glaucoma patients. Human AH analyzed under non-reducing conditions suggests that MYOC is not normally found in a monomeric form, but rather is predominantly dimeric. Although MYOC was first reported almost 20 years ago, a technical challenge still faced by researchers is an inability to isolate full-length MYOC protein for experimental purposes. Herein we describe two methods by which to isolate sufficient quantities of human full-length MYOC protein from mammalian cells. One method involved identification of a cell line (HeLa S3) that would secrete full-length protein (15 mg/L) while the second method involved a purification approach from 293 cells requiring identification and modification of an internal MYOC cleavage site (Glu214/Leu215). MYOC protein yield from 293 cells was improved by mutation of two MYOC N-terminal cysteines (C47 and C61) to serines. Analytical size exclusion chromatography of our full-length MYOC protein purified from 293 cells indicated that it is predominantly dimeric and we propose a structure for the MYOC dimer. We hope that by providing methods to obtain MYOC protein, researchers will be able to utilize the protein to obtain new insights into MYOC biology. The ultimate goal of MYOC research is to better understand this target so we can help the patient that carries a MYOC mutation retain vision and maintain quality of life.


Subject(s)
Aqueous Humor/metabolism , Cytoskeletal Proteins/chemistry , Eye Proteins/chemistry , Glycoproteins/chemistry , Protein Multimerization , Animals , Binding Sites/genetics , Blotting, Western , COS Cells , Cell Line , Chlorocebus aethiops , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/metabolism , Eye Proteins/genetics , Eye Proteins/metabolism , Glycoproteins/genetics , Glycoproteins/metabolism , HEK293 Cells , HeLa Cells , Humans , Models, Molecular , Mutation , Protein Conformation
4.
Proc Natl Acad Sci U S A ; 111(8): 3128-33, 2014 Feb 25.
Article in English | MEDLINE | ID: mdl-24520176

ABSTRACT

Defects in epigenetic regulation play a fundamental role in the development of cancer, and epigenetic regulators have recently emerged as promising therapeutic candidates. We therefore set out to systematically interrogate epigenetic cancer dependencies by screening an epigenome-focused deep-coverage design shRNA (DECODER) library across 58 cancer cell lines. This screen identified BRM/SMARCA2, a DNA-dependent ATPase of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex, as being essential for the growth of tumor cells that harbor loss of function mutations in BRG1/SMARCA4. Depletion of BRM in BRG1-deficient cancer cells leads to a cell cycle arrest, induction of senescence, and increased levels of global H3K9me3. We further demonstrate the selective dependency of BRG1-mutant tumors on BRM in vivo. Genetic alterations of the mSWI/SNF chromatin remodeling complexes are the most frequent among chromatin regulators in cancers, with BRG1/SMARCA4 mutations occurring in ∼10-15% of lung adenocarcinomas. Our findings position BRM as an attractive therapeutic target for BRG1 mutated cancers. Because BRG1 and BRM function as mutually exclusive catalytic subunits of the mSWI/SNF complex, we propose that such synthetic lethality may be explained by paralog insufficiency, in which loss of one family member unveils critical dependence on paralogous subunits. This concept of "cancer-selective paralog dependency" may provide a more general strategy for targeting other tumor suppressor lesions/complexes with paralogous subunits.


Subject(s)
DNA Helicases/deficiency , Epigenesis, Genetic/physiology , Multiprotein Complexes/genetics , Neoplasms/genetics , Nuclear Proteins/deficiency , Transcription Factors/deficiency , Transcription Factors/genetics , Blotting, Western , Cell Cycle Checkpoints/genetics , Cell Line, Tumor , Cellular Senescence/genetics , Gene Knockdown Techniques , Gene Library , Histones/metabolism , Humans , Immunoprecipitation , Multiprotein Complexes/metabolism , RNA, Small Interfering/genetics , Transcription Factors/metabolism
5.
Proc Natl Acad Sci U S A ; 108(30): 12243-8, 2011 Jul 26.
Article in English | MEDLINE | ID: mdl-21746906

ABSTRACT

The HDL receptor, scavenger receptor, class B, type I (SR-BI), is a homooligomeric cell surface glycoprotein that controls HDL structure and metabolism by mediating the cellular selective uptake of lipids, mainly cholesteryl esters, from HDL. The mechanism underlying SR-BI-mediated lipid transfer, which differs from classic receptor-mediated endocytosis, involves a two-step process (binding followed by lipid transport) that is poorly understood. Our previous structure/activity analysis of the small-molecule inhibitor blocker of lipid transport 1 (BLT-1), which potently (IC(50) âˆ¼ 50 nM) blocks SR-BI-mediated lipid transport, established that the sulfur in BLT-1's thiosemicarbazone moiety was essential for activity. Here we show that BLT-1 is an irreversible inhibitor of SR-BI, raising the possibility that cysteine(s) in SR-BI interact with BLT-1. Mass spectrometric analysis of purified SR-BI showed two of its six exoplasmic cysteines have free thiol groups (Cys251 and Cys384). Converting Cys384 (but not Cys251) to serine resulted in complete BLT-1 insensitivity, establishing that the unique molecular target of BLT-1 inhibition of cellular SR-BI dependent lipid transport is SR-BI itself. The C384S substitution reduced the receptor's intrinsic lipid uptake activity by approximately 60% without dramatically altering its surface expression, homooligomerization, or HDL binding. Thus, a small-molecule screening approach identified a key residue in SR-BI involved in lipid transport, providing a powerful springboard into the analyses of the structure and mechanism of SR-BI, and highlighting the power of this approach for such analyses.


Subject(s)
Scavenger Receptors, Class B/chemistry , Amino Acid Substitution , Animals , Binding Sites , Biological Transport, Active , COS Cells , Chlorocebus aethiops , Cyclopentanes/pharmacology , Cysteine/chemistry , Humans , In Vitro Techniques , Lipid Metabolism , Lipoproteins, HDL/metabolism , Mass Spectrometry , Mice , Models, Molecular , Mutagenesis, Site-Directed , Mutant Proteins/antagonists & inhibitors , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Scavenger Receptors, Class B/antagonists & inhibitors , Scavenger Receptors, Class B/genetics , Scavenger Receptors, Class B/metabolism , Thiosemicarbazones/pharmacology
6.
PLoS Biol ; 7(12): e1000256, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20016685

ABSTRACT

A single nucleotide substitution in intron 3 of IGF2 in pigs abrogates a binding site for a repressor and leads to a 3-fold up-regulation of IGF2 in skeletal muscle. The mutation has major effects on muscle growth, size of the heart, and fat deposition. Here, we have identified the repressor and find that the protein, named ZBED6, is previously unknown, specific for placental mammals, and derived from an exapted DNA transposon. Silencing of Zbed6 in mouse C2C12 myoblasts affected Igf2 expression, cell proliferation, wound healing, and myotube formation. Chromatin immunoprecipitation (ChIP) sequencing using C2C12 cells identified about 2,500 ZBED6 binding sites in the genome, and the deduced consensus motif gave a perfect match with the established binding site in Igf2. Genes associated with ZBED6 binding sites showed a highly significant enrichment for certain Gene Ontology classifications, including development and transcriptional regulation. The phenotypic effects in mutant pigs and ZBED6-silenced C2C12 myoblasts, the extreme sequence conservation, its nucleolar localization, the broad tissue distribution, and the many target genes with essential biological functions suggest that ZBED6 is an important transcription factor in placental mammals, affecting development, cell proliferation, and growth.


Subject(s)
Insulin-Like Growth Factor II/metabolism , Muscle Development , Repressor Proteins/metabolism , Animals , Carrier Proteins/metabolism , Cell Line , Cell Nucleolus/metabolism , Cell Proliferation , Chromatin Immunoprecipitation , DNA Transposable Elements , Gene Expression Regulation, Developmental , Genetic Diseases, Inborn , Humans , Mass Spectrometry , Mice , Nuclear Proteins , Quantitative Trait Loci , RNA Interference , RNA, Small Interfering , RNA-Binding Proteins , Swine , Wound Healing
SELECTION OF CITATIONS
SEARCH DETAIL
...